Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05278962 · ClinicalTrials.gov registry record · Phase 4
HF Patients With LVADs Being Treated With SGLT2i
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT05278962 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 32 participants.
The verdict
NCT05278962, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
Interventions
- DRUG SGLT2i
- OTHER No SGLT2i
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05278962
The ClinicalTrials.gov registry entry for NCT05278962 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SGLT2i is the first listed.
NCT05278962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05278962 about?
NCT05278962 is a clinical study titled "HF Patients With LVADs Being Treated With SGLT2i". The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
What is the current status of trial NCT05278962?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2022-09-08. Estimated completion is 2025-08-31.
What interventions are being tested in trial NCT05278962?
The interventions under investigation include: SGLT2i (DRUG), No SGLT2i (OTHER).
Who is sponsoring clinical trial NCT05278962?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.